Drug Trial News

RSS

Dengue vaccine breakthrough

Results of the first ever trial to show that a safe and effective dengue vaccine may be possible are published Online First in The Lancet.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

10 Sep 2012

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Antibiotic treatment with amoxicillin/clavulanate improves moderate exacerbations in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) and significantly prolongs the time between exacerbations, according to a new study from researchers in Spain.

10 Sep 2012

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.

7 Sep 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

7 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

6 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Drug Trial News

Dengue vaccine breakthrough

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Phase III data for Suvorexant, an investigational insomnia medicine, announced

TauRx initiates LMTX Phase 3 trial in Pick's Disease

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Crizotinib effective in shrinking tumors in patients with ALK positive non-small cell lung cancer

The Institute of Cancer Research, CRT and Astex to discover and develop novel drug candidates

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders

Clinical trial to test combination of two drugs in treating fibromyalgia

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News